Meet the Director: Propelling Proteomics Forward
We caught up with Pierre Thibault, Director of the Center for Advanced Proteomic and Chemoproteomic Analyses (CAPCA), to discuss what’s next for the center – and the field
Charlotte Barker | | Interview
With 20 years in proteomics behind him, Pierre Thibault is now a Professor of Chemistry and Biochemistry and a Principal Investigator at the Institute for Research in Immunology and Cancer at the Université de Montréal, and Director of the Center for Advanced Proteomic and Chemoproteomic Analyses (CAPCA). His group uses quantitative approaches to study the immunopeptidome of cancer cells and the molecular mechanisms and post-translational modifications governing cell signaling – with the end goal of making more personalized therapies for patients.
What is the goal of CAPCA?
CAPCA is a nationally funded facility providing analytical services to the Canadian research community. Our laboratory is equipped with cutting-edge, high-resolution accurate mass LC-MS systems that deliver high-sensitivity. We have expertise in utilizing this instrumentation in a range of areas; from protein identification to large-scale proteomic analyses (including isotopic labeling and label-free quantitation approaches), as well as deconvolution of drug mechanism of action by CRISPR/Cas9-based chemogenomic screens.
Read the full article now
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Analytical Scientist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.